Welcome to our dedicated page for COSCIENS Biopharma SEC filings (Ticker: CSCI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on COSCIENS Biopharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into COSCIENS Biopharma's regulatory disclosures and financial reporting.
COSCIENS Biopharma Inc. filed a Form 25 to remove its common shares, with no par value, from listing and/or registration on the Nasdaq Capital Market under Section 12(b) of the Securities Exchange Act of 1934.
The company certifies it has reasonable grounds to believe it meets all requirements for filing this notification, which was signed by Chief Financial Officer Giuliano La Fratta and dated August 26, 2025.
COSCIENS Biopharma Inc. furnished a Form 6-K as a foreign private issuer for August 2025, primarily to provide investors with its second quarter 2025 information package. The filing incorporates Exhibits 99.1 through 99.4 into the company’s existing Form S-8 registration statements, so these Q2 materials become part of the documents used for its equity compensation plans.
The exhibits include condensed interim consolidated financial statements for Q2 2025, management’s discussion and analysis of financial condition and results of operations for the same period, and certifications from the chief executive officer and principal financial officer under Canadian National Instrument 52-109. The report also contains an extensive forward-looking statements section outlining business expectations and key risk areas, and it directs readers to the latest Form 20-F and other SEC filings for additional risk factors.
COSCIENS Biopharma Inc. filed a report describing a press release that covers its second quarter 2025 financial results and a strategic initiatives update. The company plans to voluntarily delist its shares from the Nasdaq Capital Market while keeping its listing on the Toronto Stock Exchange, meaning trading in the United States would move off Nasdaq but the shares would remain listed in Canada. The report also incorporates the press release into several existing Form S-8 registration statements for employee equity plans. Extensive forward-looking statements highlight uncertainties around the company’s technologies, products, business strategy, discontinued research programs, facilities, clinical studies, financial resources, and overall outlook, and direct readers to previously disclosed risk factors in its latest Form 20-F.